Mollie Leoni Sells 4,963 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kura Oncology Price Performance

NASDAQ:KURA traded down $0.14 during mid-day trading on Tuesday, reaching $7.77. The stock had a trading volume of 1,544,944 shares, compared to its average volume of 1,497,249. The stock has a 50-day simple moving average of $9.23 and a two-hundred day simple moving average of $15.69. The stock has a market capitalization of $604.20 million, a PE ratio of -3.29 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in KURA. Harbor Capital Advisors Inc. increased its stake in shares of Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after purchasing an additional 3,092 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Kura Oncology by 251.5% during the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after purchasing an additional 58,422 shares during the last quarter. Quarry LP purchased a new position in Kura Oncology in the 2nd quarter valued at approximately $196,000. Finally, The Manufacturers Life Insurance Company grew its stake in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares in the last quarter.

Analyst Ratings Changes

KURA has been the subject of a number of research analyst reports. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Finally, HC Wainwright lifted their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.